Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| VSTM | Verastem, Inc. | 2025-10-16 18:41:26 | 9.82 | 0.31 | 3.26 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VSTM | 0001526119 | Verastem, Inc. | US92337C2035 | 549300IY0EFBIU8NQC81 | 273269467 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | MA | 117 KENDRICK STREET | NEEDHAM | MA | 02494 | UNITED STATES | US | (781) 292-4200 | 117 KENDRICK STREET, NEEDHAM, MA, 02494 | 117 KENDRICK STREET, NEEDHAM, MA, 02494 | — | Pharmaceutical Industry | 2010 | Brian Stuglik | 100 | https://verastem.com | 79,628,327 | 61,523,000 | 61,545,270 | Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. | 2025-10-10 21:38:43 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 79,628,327 | -107,061,182 | -57.3472 | 51,486,705 | 26,191,210 | 103.541 |
| 2023 | 186,689,509 | -29,242,555 | -13.5425 | 25,295,495 | -175,382,484 | -87.395 |
| 2022 | 215,932,064 | -480,772,213 | -69.0066 | 200,677,979 | 14,348,367 | 7.7005 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Daniel Calkins | Chief Financial Officer | 2024 | 325,000 | — | 254,079 | 124,000 | 22,690 | 741,010 |
| Daniel Paterson | Chief Executive Officer, President | 2024 | 648,000 | — | 981,000 | 356,000 | 23,890 | 2,536,767 |
| Daniel Paterson | Chief Executive Officer, President | 2023 | 544,800 | — | 1,044,000 | 330,000 | 22,790 | 3,626,857 |
| Brian M. Stuglik | Chief Executive Officer | 2023 | 389,400 | — | 0 | 421,850 | 83,392 | 2,021,126 |
| Daniel Calkins | Chief Financial Officer | 2023 | 257,529 | — | 0 | 126,000 | 18,304 | 622,564 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 78 |
| 2023 | 73 |
| 2022 | 57 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 10,000,000 | — | 2,596,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 81,334,000 | 61,356,000 | 50,558,000 |
| General And Administrative Expenses | 43,622,000 | 30,728,000 | 24,975,000 |
| Operating Expenses | 124,956,000 | 92,084,000 | 75,533,000 |
| Operating Income | -114,956,000 | -92,084,000 | -72,937,000 |
| Net Income | -130,637,000 | -87,367,000 | -73,812,000 |
| Earnings Per Share Basic | -3.66 | -3.96 | -0.38 |
| Earnings Per Share Diluted | -3.66 | -3.93 | -0.38 |
| Weighted Average Shares Outstanding Basic | 35,713,000 | 22,054,000 | 193,654,000 |
| Weighted Average Shares Outstanding Diluted | 35,713,000 | 22,054,000 | 193,654 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 88,818,000 | 77,909,000 | 74,933,000 |
| Marketable Securities Current | — | 59,220,000 | 12,961,000 |
| Accounts Receivable | — | — | 31,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 94,961,000 | 143,682,000 | 92,870,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 32,000 | 37,000 | 92,000 |
| Other Assets Non Current | 4,899,000 | 4,587,000 | 58,000 |
| Total Assets Non Current | 6,577,000 | 6,036,000 | 2,180,000 |
| Total Assets | 101,538,000 | 149,718,000 | 95,050,000 |
| Accounts Payable | 4,026,000 | 7,184,000 | 4,901,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 15,000,000 | — | — |
| Other Liabilities Current | 25,952,000 | 17,928,000 | 14,983,000 |
| Total Liabilities Current | 30,973,000 | 26,380,000 | 21,663,000 |
| Long Term Debt | 40,724,000 | 40,086,000 | 24,526,000 |
| Other Liabilities Non Current | 0 | 0 | 0 |
| Total Liabilities Non Current | 99,458,000 | 44,805,000 | 25,996,000 |
| Total Liabilities | 130,431,000 | 71,185,000 | 47,659,000 |
| Common Stock | 4,000 | 3,000 | 20,000 |
| Retained Earnings | -955,527,000 | -824,890,000 | -737,523,000 |
| Accumulated Other Comprehensive Income | — | 13,000 | — |
| Total Shareholders Equity | -28,893,000 | 57,374,000 | 47,391,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 26,000 | 62,000 | 118,000 |
| Share Based Compensation Expense | 7,342,000 | 5,860,000 | 6,047,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | -31,000 | -485,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -3,158,000 | 2,283,000 | 2,599,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -104,771,000 | -86,460,000 | -63,673,000 |
| Purchases Of Marketable Securities | — | 96,447,000 | 17,815,000 |
| Sales Of Marketable Securities | 60,000,000 | 52,000,000 | 84,000,000 |
| Acquisition Of Property Plant And Equipment | 28,000 | — | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 59,972,000 | -44,447,000 | 66,185,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 14,221,000 | 91,420,000 | 27,354,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | 300,000 | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 54,782,000 | 134,194,000 | 51,784,000 |
| Change In Cash | 9,983,000 | 3,287,000 | 54,296,000 |
| Cash At End Of Period | 88,818,000 | 77,909,000 | 74,933,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 3,774,000 | 3,361,000 | 1,536,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -3.66 | -3.96 | -0.38 |
| Price To Earnings Ratio | -1.4126 | -2.0556 | -12.7111 |
| Earnings Growth Rate | -7.5758 | 942.1053 | -7.3171 |
| Price Earnings To Growth Ratio | 0.1865 | -0.0022 | 1.7372 |
| Book Value Per Share | -0.809 | 3.5609 | 0.2447 |
| Price To Book Ratio | -6.3903 | 2.2859 | 19.7377 |
| Ebitda | -126,049,000 | -83,166,000 | -71,557,000 |
| Enterprise Value | 151,542,210 | 141,696,560 | 884,980,550.8 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -1.9286 | 0.6987 | 0.5175 |
| Capital Expenditures | 21,000 | 7,000 | 0 |
| Free Cash Flow | -104,792,000 | -86,467,000 | -63,673,000 |
| Return On Equity | 4.5214 | -1.5228 | -1.5575 |
| One Year Beta | 1.5575 | 2.4035 | 1.5688 |
| Three Year Beta | 1.7297 | 1.6923 | 1.4201 |
| Five Year Beta | 1.504 | 1.4823 | 1.3759 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Bunn Paul A. | Director | 2025-10-09 | 8,333 | D | 8,333 |
| Calkins Daniel | Chief Financial Officer | 2025-09-24 | 25 | D | 109,838 |
| Calkins Daniel | Chief Financial Officer | 2025-09-22 | 57 | D | 109,863 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| CWM, LLC | 2025-09-30 | 5,000 | 557 | 8.9767 |
| Farther Finance Advisors, LLC | 2025-09-30 | 1,113 | 126 | 8.8333 |
| GAMMA Investing LLC | 2025-09-30 | 547 | 62 | 8.8226 |
| NEW YORK STATE COMMON RETIREMENT FUND | 2025-06-30 | 21,762 | 5,200 | 4.185 |
| OSAIC HOLDINGS, INC. | 2025-06-30 | 24,021 | 5,789 | 4.1494 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 228 | 1,406.76 | 0.0006 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 37,544 | 231,646.48 | 0.0098 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 22,979 | 141,780.43 | 0.0108 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 27,459 | 169,422.03 | 0.0006 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Extended Market Index Fund | FZIPX | 16,461 | 101,564.37 | 0.0055 |